Author

Julius Nangosyah

Institution: Cytel (United States)

Observed institutions: Janssen (Belgium), Cytel (United States)

OpenAlex ID: A5033075840

Drug‐Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ‐56136379 (Bersacapavir)

2022 · Joris Vandenbossche, Jeysen Yogaratnam, et al. · Clinical Pharmacology in Drug Development · 7

Pharmacokinetics of JNJ‐73763989 and JNJ‐56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment

2023 · Thomas N. Kakuda, Atef Halabi, et al. · The Journal of Clinical Pharmacology · 6

Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial

2024 · Veronica V. Rezelj, Fred Paddenburg, et al. · Vaccines · 1

Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life

2021 · Madhu Sanga, Subusola Vaughan, et al. · International Journal of Clinical Pharmacology and Therapeutics · 1

Works count: 4

Citation count: 15

H-index: 2

I10-index: